



Aastrom Biosciences Issues Correction of Wall Street Journal Article

-- Adult Bone Marrow Stem Cells are Company Focus --

Ann Arbor, Michigan, November 11, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today issued the following response to an article published in the November 4th, 2004 issue of The Wall Street Journal.

In an article entitled: "Another Winner is Big Business" published in the November 4th issue of The Wall Street Journal, Aastrom Biosciences was described as a biotechnology firm doing embryonic stem-cell research, which it is not accurate.

Aastrom Biosciences is a regenerative medicine company developing therapeutic products for the repair or regeneration of damaged human tissues and other medical disorders, or the generation of normal human tissues, utilizing only stem and progenitor cells derived from adult bone marrow. Aastrom Biosciences does not utilize embryonic stem cells in any of its research and development.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a regenerative medicine company developing proprietary adult stem cell-based products for the repair of damaged human tissues and other medical disorders, or the generation of normal human tissues. Aastrom's strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), which are now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

For more information, visit Aastrom's website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning product development objectives, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "planning," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are future clinical trial results, regulatory approval requirements, the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:

Kris M. Maly or Becky Anderson
Investor Relations Department
Aastrom Biosciences, Inc.
Phone: (734) 930-5777

Kevin McGrath
Cameron Associates
Phone: (212) 245-4577